Challenges in tuberculosis drug research and development: Commentary

Nature Medicine

Volumn 13, Issue 3, 2007, Pages 290-294

  Ginsberg, Ann M ^a   Spigelman, Melvin ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ETHYLENEDIAMINE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LL 3858; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OPC 67683; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN; SQ 109; SUDOTERB; TMC 207; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HUMAN; MORTALITY; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; DRUG DESIGN; DRUG INDUSTRY; HUMANS; TUBERCULOSIS;

EID: 33847704942     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0307-290     Document Type: Note

References (31)

1. Cape Town Declaration. 〈http://www.tballiance.org/pdf/CapeTownDecl. pdf〉 (2000).
2. Dye, C. Lancet 367, 938-940 (2006).
3. Zignol, M. et al. J. Infect. Dis. 194, 479-485 (2006).
4. Donald, P. et al. Am. J. Respir. Crit. Care Med. 156, 895-900 (1997).
5. WHO Expert Group on XDR-TB. 〈http://www.who.int/tb/xdr/faqs/en/ index.html〉 (2006).
6. Centers for Disease Control and Prevention. MMWR Morb. Mortal. Wkly. Rep. 55, 301-305 (2006).
7. Gandhi, N.R. et al. Lancet 368, 1575-1580 (2006).
8. World Health Organization. 〈http://www.who.int/mediacentre/news/ notes/2006/np23/en/index.html〉 (2006).
9. Dean, G.L. et al. AIDS 16, 75-83 (2002).
10. Global Alliance for TB Drug Development. Tuberculosis (Edinb.) 81 (suppl. 1), 1-52 (2001).
11. Park-Wyllie, L.Y. et al. N. Engl. J. Med. 354, 1352-1361 (2006).
12. Burman, W.J. et al. Am. J. Respir. Crit. Care Med. 174, 331-338 (2006).
13. Nuermberger, E. et al. Am. J. Respir. Crit. Care Med. 170, 1131-1134 (2004).
14. Andries, K. et al. Science 307, 223-227 (2005).
15. McNeeley, D. Open Forum II on Key Issues in TB Drug Development, London, 11 December 2006. 〈http://www.kaisernetwork.org/health_cast/uploaded_files/ McNeeley,_David_(12-12)_TMC207.pdf〉.
16. Stover, C.K. et al. Nature 405, 962-966 (2000).
17. Manjunatha, U.H. et al. Proc. Natl. Acad. Sci. USA 103, 431-436 (2006).
18. Hittel, N. Open Forum II on Key Issues in TB Drug Development, London, 11 December 2006. 〈http://www.kaisernetwork.org/health_cast/uploaded_files/ Hittel,_Norbert_(12-12)_OPC_67683.pdf〉 (2006).
19. Arora, S. International Union against TB and Lung Disease, New Drugs Symposium, Paris, 31 October 2004.
20. Protopopova, M. et al. J. Antimicrob. Chemother. 56, 968-974 (2005).
21. Chen, P. et al. J. Antimicrob. Chemother. 58, 332-337 (2006).
22. Nacy, C. Open Forum II on Key Issues in TB Drug Development, London, 11 December 2006. 〈http://www.kaisernetwork.org/health_cast/uploaded_files/ Nacy,_Carol_(12-12)_SQ109.pdf〉 (2006).
23. Grosset, J. & Ji, B. In Mycobacteria, Vol. II: Chemotherapy (eds. Gangadharam, P.R.J. & Jenkins, P.A.) 51-97 (Chapman & Hall, New York, 1998).
24. Pyle, M.M. Proc. Staff Meetings Mayo Clinic 22, 465 (1947).
25. Daniels, M. & Hill, A.B. BMJ 1, 1162-1168 (1952).
26. Medical Research Council Investigations. BMJ 2, 769-782 (1948).
27. Selkon, J.B. et al. Bull World Health Organ. 31, 273-294 (1964).
28. US Food and Drug Administration. 〈http://www.fda.gov/oc/combination/ innovative.html#drugbiolconstit〉 (2006).
29. Mitchison, D.A. J. Antimicrob. Chemother. 58, 494-495 (2006).
30. The Tuberculosis Trials Consortium. Lancet 360, 528-534 (2002).
31. Goldberger, M. 〈http://www.tballiance.org/downloads/of2005/ 2005_openforum_summary.pdf〉 (2005).